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Role of the CDKN1A/p21, CDKN1C/p57, and CDKN2A/p16 Genes  in the 
Risk of  Atherosclerosis and  Myocardial Infarction
AbstRACt
Atherosclerosis is characterized by excessive proliferation of neointimal leukocytes 
and vascular smooth muscle cells (VSMCs). In mice, the manipulation of cell cycle 
inhibitors such as CDKN1B (p27) and CDKN1A (p21) modifies the risk of developing 
atherosclerosis. In humans, CDKN1A, CDKN1B and CDKN1C (p57) are differentially 
expressed in normal versus atherosclerotic vessels. A DNA‑polymorphism within the 
CDKN1B promoter has been associated with myocardial infarction (MI). In the present 
study, we analyzed the effect of CDKN1A, CDKN1C and CDKN2A (p16) polymorphisms 
on MI‑risk.
A total of 316 patients (all male, < 55 years) and 434 controls were genotyped, 
and the allele and genotype frequencies were compared between the two groups. Two 
CDKN1C polymorphisms, a promoter GT‑repeat and a variable number of repeats of 
the amino acid PAPA‑motif, were associated with MI. The presence of two alleles ≤ 
11‑repeats (9/11, 10/11 and 11/11 genotypes) was significantly less frequent among 
patients (p < 0.001). This difference was also significant when analyzing the subpopula‑
tion of smokers (p = 0.004), suggesting a protective role for these low‑repeat genotypes 
(OR = 0.49, 95%CI = 0.32–0.73). The PAPA‑BB homozygotes were significantly less 
frequent in patients, but this could be attributed to a linkage disequilibrium between the 
11‑repeats and B alleles. No significantly different frequencies between patients and 
controls for the four CDKN1A (‑1026A/G, ‑754G/C, ‑369G/C and Ser31Arg) and the 
three CDKN2A (‑523 G/A, +22 G/A and Ala148Thr) polymorphisms was found. In 
conclusion, we provide here genetic evidence for the association between DNA‑variants 
in the CDKN1C/p57 gene and the risk of atherosclerosis and MI.
IntRoduCtIon
Abnormal	 proliferation	 of	 leukocytes	 and	 vascular	 smooth	 muscle	 cells	 (VSMCs)	
within	 the	 artery	 wall	 is	 a	 hallmark	 of	 the	 atherosclerotic	 process.1	This	 pathological	




cyclin-CDK	complexes	are	 inhibited	by	 the	 reversible	association	with	CDK	inhibitory	
proteins	 (CKIs)	 of	 the	 Ink4	 (p16Ink4a,	 p15Ink4b,	 p18Ink4c	 and	 p19Ink4d)	 and	 Cip/Kip	
(p21cip1,	p27kip1	and	p57kip2)	families.2
In	 recent	 years,	 accumulating	 evidence	 has	 implicated	 various	 CKIs	 as	 important	





in	 primary	 atherosclerotic	 and	 restenotic	 tissue	 versus	 nondiseased	 arterial	 tissue.11-13	






VSMCs,	mitogen-dependent	G1-to-S	 transition	 coincided	with	downregulation	of	 p57	
























tion.	These	 findings	 suggest	 that	 the	 absence	 of	 p21	 expression	 in	
neointimal	macrophages	is	important	to	the	beneficial	effect	against	
atherosclerosis,	 possibly	 due	 to	 the	 prevention	 of	 p21-dependent	
induction	of	 inflammatory	 responses	 in	macrophages.18	Compared	




Both	 acquired/environmental	 (e.g.,	 smoking,	 hypertension	 and	
hypercholesterolaemia)	 and	 inherited/genetic	 factors	 contribute	 to	
the	 development	 of	 atherosclerotic	 lesions	 and	 their	 clinical	mani-
festation,	 such	 as	 coronary	 artery	 disease	 (CAD)	 and	 associated	
ischaemic	events.	Among	others,	polymorphisms	in	the	components	
of	 the	 renin-angiotensin	 system,	 nitric	 oxide	 synthases,	 apolipo-
proteins,	 and	 several	 cytokines/chemokines	 and	 growth	 factors	
could	 modulate	 the	 risk	 of	 suffering	 CAD.20	 These	 polymorphic	






allele	 among	MI	 patients.21	 In	 addition,	 this	 allele	 was	 associated	
with	 significantly	 lower	CDKN1B	 gene	 promoter	 activity	 in	 vitro,	













for	 MI	 (chest	 pain,	 electrochardiographic	 changes	 and	 elevated	
enzymatic	 blood-levels).22	 These	 patients	 underwent	 coronary	




Patients	 were	 defined	 as	 hypertensives	 if	 they	 had	 a	 documented	
history	of	hypertension,	with	a	systolic	blood	pressure	>140	mmHg	
in	more	 than	one	determination.	Patients	with	 a	history	of	hyper-





The	 control	 group	 consisted	 of	 434	 male	 healthy	 individuals	






Polymerase chain reaction genotyping.	 Blood	 (10	 ml)	 was	
collected	 from	 patients	 and	 controls,	 and	 the	 genomic	 DNA	 was	
extracted	 from	 the	 leukocytes	 following	 a	 salting-out	 method.25	
Polymerase	 chain	 reaction	 (PCR)	was	 used	 to	 amplify	 the	 specific	
fragments	containing	the	polymorphic	sites.	Table	2	summarizes	the	
primer	sequences	and	the	conditions	to	genotype	each	polymorphism.	
PCR	primers	were	 derived	 from	 the	UCSC	genome	 sequences	 for	
CDKN1A	(NM-078467),	CDKN1C	(NM-000076),	and	CDKN2A	
(NM-000077)	 (www.genome.ucsc.edu).	 Each	 PCR	 consisted	 of	
100	ng	of	DNA,	10	pmol	of	 each	primer	pair,	2	mM	MgCl2,	1X	






by	 electrophoresis	 on	 agarose	 gels,	 automated	 capillary	 electropho-
resis,	 or	 single	 strand	 conformation	 analysis	 (SSCA).	 In	 order	 to	
confirm	 the	 accuracy	 of	 these	 genotyping	methods,	 we	 sequenced	
samples	 representative	 of	 each	 genotype	 through	direct	 sequencing	
of	 PCR-fragments,	 using	 BigDye	 chemistry	 and	 an	 ABI	 PRISM	
310	system	(Applied	Biosystems).	In	addition,	each	set	of	PCR	and	
genotyping	 assays	 included	 samples	 from	 the	possible	 genotypes	 as	
positive	quality-controls.
CDKN1C/p57 polymorphisms.	 The	 GT	 dinucleotide	 repeat	
polymorphism	 is	 at	 the	 5'	 upstream	 (promoter)	 region	 of	 the	









mixed	 with	 20	 ml	 of	 formamide	 and	 denatured,	 and	 5	 ml	 were	
Table 1	 Clinical,	biochemical	and	anthropometric		 	
	 characteristics	of	patients	and	controls
  Patients Controls 
  (n = 316) (n = 434)
 Mean age ± SD (years)1 45 ± 7 48 ± 7
 Male 316 (100%) 434 (100%)
 Smokers2 294 (93%) 156 (36%)
 Hypertensives3 114 (36%) 65 (15%)
 Total cholesterol (mg/dl)4 222 ± 58 203 ± 38
 Hypercholesterolaemics 57 (18%) 65 (15%) 
 (total cholesterol >250 mg/dl)  
 HDL‑cholesterol (mg/dl)5 33 ± 9 51± 12
 Triglycerides (mg/dl)6 161 (95)  109 (81)
1p < 0.05, mean age in patients vs. controls; 2p < 0.0001; OR = 21.68, 95%CI = 13-35, patients vs. 
controls; 3sistolic blood pressure > 140 mmHg; p < 0.0001; OR = 2.96, 95%CI = 2.19-4.01.; 4p < 






























Two	 single	nucleotide	polymorphisms	 (SNPs)	 in	 the	CDKN2A	







CDKN1A/p21 polymorphisms.	We	analyzed	 three	SNPs	 in	 the	
5'-promoter	sequence	of	the	CDKN1A/p21	gene:	-1026	A/G,	-754	
G/C,	 and	 -369	 G/C.	 For	 genotyping	 -1026	 A/G	 the	 DNA	 was	










morphism,	 a	 fragment	 of	 240	bp	was	PCR-amplified	 and	patients	
and	controls	were	genotyped	through	SSCA,	as	described	above.
Statistical analysis.	 Frequencies	 of	 genotypes	 and	 alleles	 in	
patients	 and	 controls	 were	 compared	 through	 a	 Yate´s	 corrected	
Chi-squared	 test.	The	Chi2	was	 also	 used	 to	 analyse	 the	 deviation	
from	the	Hardy-Weinberg	equilibrium	of	the	genotype	frequencies.	
Odds	 ratio	 (OR)	 and	 the	95%	confidence	 intervals	 (CI)	were	 also	
obtained	to	calculate	the	relative	risk	of	MI	conferred	by	each	geno-




Clinical and biochemical data.	 Table	 1	 summarizes	 the	 main	
characteristics	of	patients	and	controls.	Early	MI	was	strongly	asso-
ciated	with	 smoking	 in	our	population	 (p	< 0.0001;	OR	=	21.68,	
95%CI	=	13.5–35.1).	In	addition,	we	found	a	higher	frequency	of	
hypertensives	 among	 patients	 (p	< 0.001).	 Compared	 to	 controls,	
patients	 displayed	 significantly	 higher	 mean	 total	 cholesterol	 and	





 Polymorphism* Primers ** size # Genotyping Allele‑sizes & 
 CDKN1C
 ‑1120 (GT)n F‑CCTGGCTGGGGTGAAGCA 146 bp Capillary electrophoresis 142 (9‑repeats) to
 (rs34738237) R‑CCGAGGTCATAGGGGAAGGG   150 (13‑repeats)
 PAPA repeat F‑GAGGCGCCGGAGCAGCT 300 bp SSCA SSCA
  R‑CTGGTTCGCGCCCTGCTC   
 CDKN1A    
 ‑1026 A/G F‑CATTTCTTTGCTGCATGATCTGAGTT 186 bp RFLP A:186 bp
 (rs2395655) R‑CCCTACACTCACCTGAACAGAAGG  (Hinf I) G:166+20 bp
 ‑754 G/C F‑GTTCAGTGGACCTCAATTTCCTC 272 bp RFLP G: 272 bp
 (rs730506) R‑ACTCTGGCAGGCAAGGATTTA  (DdeI) A: 152+120 bp
 ‑369 G/C F‑GATTTGTGGCTCACTTCGTGGGG 153 bp RFLP G: 153 bp
 (rs4135239) R‑GCTCCTGGCTGCCCAGCGT  (Taq I) C: 134 +19 bp
 S31R F‑CATGCGGCAGCAAGGCCTG 240 bp SSCA SSCA
 (rs1801270) R‑CTCCTCCCAACTCATCCCGG
 CDKN2A    
 ‑523 G/A F‑CATCTTTTCAGAGTCTGCTC 346 bp SSCA SSCA
 (rs 3731238) R‑CCTAACTGCCAAATTGAATC
 +22 G/A F‑CCCTATGACACCAAACAC 366 bp SSCA SSCA
 (rs3814960) R‑GGTATCTTTCCAGGCAAG
 A148T F‑CTGGACGTGCGCGATGCCTG 307 bp RFLP A: 126+148 bp
     (rs3731249)  R‑GCAGGGCGATAGGGAGACTC                    (BstUI)    G:126+133+38 bp
For those polymorphisms genotyped through RFLP, the restriction enzyme and the size of the alleles are also indicated. *The reference number for each polymorphism was obtained from the ENSEMBL 
database (www. Ensembl.org). The PAPA-repeat has no reference number in this database. ** F: forward primer; R: reverse primer. # Size of the PCR fragment in base pairs (bp). & Alleles in the 



















CDKN1C GT and PAPA‑repeat polymorphisms.	The	
GT-repeat	 of	 the	CDKN1C	 gene	 is	 localized	 at	 position	
-1120	 from	 the	 transcription	 initiation	 site.	 We	 found	
in	 our	 population	 individuals	 carrying	 alleles	 containing	
between	9	 and	13	 repeats.	Alleles	with	9	 and	10	 repeats	
were	rare	(allele	frequency	<	1.5%;	Table	3).	We	genotyped	
the	 316	MI-patients	 and	434	 controls	 for	 this	 polymor-
phism,	and	 found	a	 significantly	higher	 frequency	of	 the	
12	 and	 13-repeat	 alleles	 compared	 to	 the	 9,	 10,	 and	 11	
alleles	 among	 the	 patients	 (p	 < 0.001).	 Carriers	 of	 two	
alleles	≤ 11-repeats	 (9/11,	10/11,	11/11	genotypes)	were	
significantly	 less	 frequent	 among	 patients	 (p<0.001).	
When	 we	 analyzed	 the	 subpopulation	 of	 smokers,	 the	
difference	between	patients	and	controls	remained	signifi-
cant	 (p	 =	 0.004),	 suggesting	 a	 protective	 role	 for	 the	




We	 found	 four	 alleles	 for	 the	CDKN1C	 PAPA-repeat	
polymorphism.	 Table	 4	 shows	 the	 distribution	 of	 the	
PAPA-genotypes	 in	 patients	 and	 controls.	 Individuals	
homozygous	 for	 the	 B	 allele	 were	 significantly	 more	
frequent	among	the	controls	(p	=	0.04).	When	we	analysed	





respectively).	We	also	 investigated	 the	distribution	of	 the	
GT-polymorphism	 according	 to	 the	 PAPA-genotypes.	
Among	the	BB-controls	(n	=	35),	87%	were	11/11-homo-
zygotes,	 while	 all	 the	 BB-patients	 (n	 =	 13)	 were	 11/11.	
Therefore,	the	observed	protective	effect	of	the	BB	geno-
type	may	 be	 a	 consequence	 of	 its	 transmission	 with	 the	
11/11	genotype.
CDKN1A and CDKN2A polymorphisms.	We	did	not	
find	significantly	different	allele	and	genotype	frequencies	
between	patients	and	controls	for	the	four	CDKN1A/p21	
polymorphisms	 analysed	 (Table	 5).	 Likewise,	 allele	 and	
genotype	 frequencies	 of	 three	 polymorphisms	 in	 the	
CDKN2A/p16	 gene	 did	 not	 differ	 between	 patients	 and	
controls	(Table	6).	This	lack	of	association	was	maintained	









particularly	 for	 those	of	 the	Cip/Kip	family,	as	regulators	
of	 arterial	 cell	 proliferation	 and	 atheroma	 development.3	We	 had	







them	 could	 have	 a	 functional	 effect	 because	 have	 been	 previously	
related	with	the	risk	of	developing	cancer.
We	 found	 a	 significantly	 reduced	 frequency	 of	 carriers	 of	 two	
low-repeat	(9,	10,	and	11)	alleles	in	the	CDKN1C	promoter	among	
Table 3	 Frequency	of	the	GT‑repeat	genotypes	and	alleles		 	
	 in	the	CDKN1C	promoter	in	patients	and	controls	(%)
 (Gt)n Genotypes Patients  Controls  Patients smokers  Controls smokers 
  (n = 316) (n = 434) (n = 294) (n = 156)
 9/11* 4 (1) 9 (2) 4 (1) 6 (4)
 9/12 2 (<1) 2 (<1) 2 (<1) 2 (1)
 9/13 1 (<1) 0 1 (<1) 0
 10/11* 1(<1) 6 (1) 0 2 (1)
 10/12 2 (<1) 0 (<1) 2 (<1) 0
 11/11* 101 (32) 194 (45) 95 (32) 70 (45)
 11/12 112 (34) 145 (33) 108 (38) 47 (30)
 11/13 51 (16) 37 (9) 44 (14) 14 (9)
 12/12 23 (7) 27 (6) 23 (8) 8 (5)
 12/13 16 (5) 14 (3) 13 (4) 7 (5)
 13/13 3 (<1) 0 2 (<1) 0
 (GT)n alleles N = 632 N = 868 N = 588 N = 312
 9 7 (1) 11 (1) 7 (1) 8 (3)
 10 3 (<1) 6 (<1) 2 (<1) 2 (<1)
 11 370 (59) 585 (67) 346 (59) 209 (67)
 12 178 (28) 215 (25) 171 (29) 72 (23)
           13    74 (12)         51 (6)  62 (11)              21 (7)
* carriers of two alleles ≤ 11-repeats (11/11+10/11+9/11); p < 0.0001; OR = 0.54, total patients vs. total controls; 
P = 0.0004; OR = 0.49, 95%CI = 0.32-0.73; smokers, patients vs. controls
Table 4	 Frequencies	of	the	PAPA‑repeat	genotypes	and	alleles		
	 in	the	CDKN1C	gene	in	patients	and	controls	(%)
 PAPA  Patients  Controls  Patients  Controls  
 Genotypes# (n = 316) (n = 434) smokers smokers  
    (n = 294) (n = 156)
 AA 153 (48) 208 (47) 139 (47) 66 (42)
 AB 140 (44) 178 (41) 132 (45) 69 (44)
 BB* 13 (4) 35 (8) 11 (4) 14 (9)
 AC 5 (1) 9 (2) 5 82) 4 (3)
 AD 1 (<1) 1 (<1) 1 (<1) 1 (<1)
 BC 3 (1) 1 (<1) 1 (<1) 1 (<1)
 CD 1 (<1) 0 1 (<1) 0
 BD 0 1 (<1) 0 0
 CC 0 1 (<1) 0 1 (<1)
 PAPA Alleles n = 632 n = 868 n = 588 n = 312 
 A 452 (72) 604 (70) 422 (72) 206 (66)
 B 169 (27) 250 (29) 157 (27) 98 (31)
 C 9 (1) 12 (81) 7 (1) 7 (82)
       D 2 (<1)          2 (<1)      2 (<1)               1 (<1)
* p = 0.04 (BB vs. the other genotypes), total patients vs. total controls; p = 0.037 (OR = 0.39, 95%CI = 0.17-0.91), 
patients smokers vs. control smokers; # A: Normal (complete) sequence; B: 12 bp deletion (APVA sequence); C: 24 bp 



















the	 patients.	 This	 association	 was	 maintained	 when	 patients	 and	
controls	 were	 matched	 for	 classical	 cardiovascular	 risk	 factors	
(smoking,	 hypercholesterolaemia,	 hypertension).	 Previous	 studies	
have	 suggested	 that	 the	 antiproliferative	 effect	 of	 p57	may	 protect	
against	 neointimal	 lesion	 development.	 Nakano	 et	 al	 found	 that	
p57	 downregulation	 was	 involved	 in	 the	 progression	 through	 the	
cell	cycle	in	the	VSMCs	from	embryonic	rat	thoracic	aorta.17	After	
mitogenic	 stimulation	 of	 quiescent	 cells,	 the	 level	 of	 p57	 rapidly	
decreased	 coinciding	 with	 the	 activation	 of	 G1	 cyclin/CDKs.	
Moreover,	 forced	 overexpression	 of	 p57	 inhibited	 the	 activation	 of	
G1	cyclin/CDKs,	prevented	the	subsequent	hyperphosphorylation	of	
retinoblastoma	proteins,	and	blocked	the	G1/S	transition	of	the	cell	




delivery	 of	 p57	 overexpressing	 adenovirus	 significantly	 suppressed	
neointimal	lesion	formation	in	balloon-injured	rabbit	carotid	artery.
The	 CDKN1C-microsatellite	 polymorphism	 is	 located	 in	 the	




polymorphisms	 in	 the	 promoter	 of	 the	 heme	 oxygenase-1	 and	
matrix	metalloproteinase-9	 genes	 have	 been	 associated	with	 angio-
graphic	 restenosis	 after	 coronary	 stenting	 and	 the	 progression	 of	







We	 found	 a	 protective	 effect	 for	 the	 PAPA-BB	 genotype.	 The	
PAPA-repeat	 is	 in	 the	 proline-rich	 domain	 of	 p57,	 and	 is	 not	
conserved	 between	 humans	 and	mice.33,34	This	 suggests	 a	 lack	 of	
functional	 effect	 of	 this	 gene	 variation,	 and	 could	 explain	 the	 lack	
of	 association	with	 some	 diseases,	 such	 as	 breast	 cancer.34	Because	
the	 B-allele	 is	 in	 linkage	 disequilibrium	with	 the	 11-repeats	 allele,	
the	protective	effect	observed	 in	 the	present	 study	could	be	due	 to	
the	existence	of	 a	 common	B-11	haplotype.	We	also	analyzed	 four	
CDKN1A	 and	 three	CDKN2A	 polymorphisms	 which	 covered	 the	
promoter	and	transcribed	regions.	Our	results	revealed	no	association	
between	the	risk	of	suffering	MI	and	none	of	these	polymorphisms.	




Our	 study	 has	 some	 limitations.	 First,	 we	 analyzed	 a	 limited	
number	 of	 patients.	 However,	 the	 total	 number	 of	 patients	 and	
controls	was	sufficient	to	reach	a	statistical	power	> 80%	for	all	the	
genotype	comparisons.	Second,	the	possibility	of	false-positive	results	
due	 to	 population	 stratification	must	 be	 considered	 in	 association	
studies,	but	this	is	unlikely	to	occur	in	our	study	because	we	analysed	
individuals	from	a	homogeneous	Caucasian	population.	In	addition,	
genotype	 frequencies	 for	 the	CDKN1A,	CDKN1C	 and	CDKN2A	
polymorphisms	 analysed	 were	 in	 the	Hardy-Weinberg	 equilibrium	
in	both	groups,	 suggesting	 that	 the	observed	 frequencies	 are	 repre-
sentative	of	cases	and	controls.	Third,	the	controls	in	our	study	were	
not	angiographically	evaluated.	Coronographic	analysis	is	potentially	
dangerous,	 and	 was	 only	 performed	 in	 the	 patients	 for	 diagnostic	
purposes.	 Thus,	 the	 role	 of	 these	 polymorphisms	 in	 modulating	
the	 origin	 of	 atherosclerotic	 plaque	 could	 not	 be	 established,	 and	
our	 study	could	underestimate	 the	 risk	conferred	by	 the	CDKN1C	
GT-repeat	polymorphism	if	it	was	associated	with	the	risk	of	devel-
oping	atherosclerosis.
In	 conclusion,	 we	 have	 found	 a	 significant	 association	 between	
MI	 in	 patients	 with	 atherosclerotic	 vessels	 and	microsatellite	 vari-
ants	within	the	CDKN1C	promoter.	If	confirmed	in	larger	cohorts,	
genotyping	of	the	CDNK1C	GT-repeat	could	be	a	valuable	tool	to	
quantify	 the	 individual	 risk	 of	 suffering	 MI.	 Also,	 this	 polymor-
phisms	could	be	 analysed	as	 a	pharmacogenetic	marker	 in	patients	
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